A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

NCT04207463 ↗

Phase 2 Unknown 150 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

AK105 is a humanized monoclonal antibody that specially binds to PD-1. Anlotinib is a small molecule tyrosine kinase inhibitor. Based on the mechanism study, tumor vascular abnormalities promote tissue hypoxia and increase lactic acid, thereby activating immunosuppression and inhibiting T cell function. Anti-angiogenic drugs enhance the infiltration of effector immune cells by inducing normalization of blood vessels and reducing immunosuppression.

Timeline

Start: 2020-06-03
Primary completion: 2020-12-31
Completion: 2021-05-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	—	Oral
Subject	Penpulimab	Monoclonal antibody	200 mg	Intravenous

Indications

No indication recorded.